Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "9058", "attributes": { "award_id": "75N93019C00015-P00001-9999-2", "title": "NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-21", "end_date": "2021-06-20", "award_amount": 668265, "principal_investigator": { "id": 24151, "first_name": "THOMAS", "last_name": "DENNY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.", "keywords": [ "2019-nCoV", "Biological Assay", "Biostatistical Methods", "Blood", "Blood specimen", "COVID-19", "Cells", "Clinical Trials", "Data", "Diagnosis", "Enrollment", "Ensure", "HIV", "Infection", "Inpatients", "Laboratories", "Methods", "Multi-site clinical study", "National Institute of Allergy and Infectious Disease", "Natural History", "Outpatients", "Patients", "Performance", "Plasma", "Quality Control", "Reagent", "Research", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "Saliva", "Sampling", "Serum", "Site", "Swab", "Testing", "Time", "Tube", "Validation", "Viral", "Viral Load result", "Virus", "pathogenic virus", "programs", "quality assurance", "virology" ], "approved": true } }, { "type": "Grant", "id": "9075", "attributes": { "award_id": "75N92020P00146-P00012-0-1", "title": "TO MODIFY THE CONTRACT AND ADD ADDITIONAL FUNDING TO CONFIGURE A SMARTPHONE AND WEB-BASED DIGITAL HEALTH SOLUTION TO SUPPORT THE GENERAL PUBLIC USE OF", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-08", "end_date": "2022-06-07", "award_amount": 2358083, "principal_investigator": { "id": 24877, "first_name": "VIK", "last_name": "KHETERPAL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1793, "ror": "", "name": "CAREEVOLUTION, INC.", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1793, "ror": "", "name": "CAREEVOLUTION, INC.", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) requires a system that can be managed by a study team and that will support general public use of SARS-CoV-2 diagnostic tests performed in a home setting. The platform must be easily accessible on a mobile device, support a variety of surveys, display test-specific usage instructions, provide guidance to the user on actions to take following test results, provide reminder notifications for test frequency, record the test results, integrate with technologies that provide test interpretation (as available), and report results to public health authorities as applicable and authorized by the user. It must additionally make all these data available to the study team for future analysis, when this is within the remit of the IRB approval for the study.", "keywords": [ "Apple", "COVID-19 diagnostic", "Cellular Phone", "Clinical Trials", "Communication", "Communities", "Contractor", "Contracts", "Custom", "Data", "Data Collection", "Data Storage and Retrieval", "Diagnostic tests", "Enrollment", "Ensure", "Event", "Feedback", "Focus Groups", "Frequencies", "Funding", "Future", "General Population", "Health Services Accessibility", "Home", "Individual", "Institutional Review Boards", "Instruction", "Internet", "Language", "Manuals", "Market Research", "National Institute of Biomedical Imaging and Bioengineering", "Notification", "Observational Study", "Online Systems", "Participant", "Personal Health Records", "Play", "Privacy", "Public Health", "Reaction", "Readability", "Reporting", "Secure", "Specific qualifier value", "Surveys", "Symptoms", "System", "Technology", "Test Result", "Testing", "Time", "Vaccination", "authority", "base", "diaries", "digital", "digital health", "handheld mobile device", "home test", "repository" ], "approved": true } }, { "type": "Grant", "id": "9076", "attributes": { "award_id": "75N92020P00146-P00005-0-1", "title": "TO MODIFY THE CONTRACT AND ADD ADDITIONAL FUNDING TO CONFIGURE A SMARTPHONE AND WEB-BASED DIGITAL HEALTH SOLUTION TO SUPPORT THE GENERAL PUBLIC USE OF", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-08", "end_date": "2021-02-15", "award_amount": 4272000, "principal_investigator": { "id": 24877, "first_name": "VIK", "last_name": "KHETERPAL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1793, "ror": "", "name": "CAREEVOLUTION, INC.", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1793, "ror": "", "name": "CAREEVOLUTION, INC.", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) requires a system that can be managed by a study team and that will support general public use of SARS-CoV-2 diagnostic tests performed in a home setting. The platform must be easily accessible on a mobile device, support a variety of surveys, display test-specific usage instructions, provide guidance to the user on actions to take following test results, provide reminder notifications for test frequency, record the test results, integrate with technologies that provide test interpretation (as available), and report results to public health authorities as applicable and authorized by the user. It must additionally make all these data available to the study team for future analysis, when this is within the remit of the IRB approval for the study.", "keywords": [ "Apple", "COVID-19 diagnostic", "Cellular Phone", "Clinical Trials", "Communication", "Communities", "Contractor", "Contracts", "Custom", "Data", "Data Collection", "Data Storage and Retrieval", "Diagnostic tests", "Enrollment", "Ensure", "Event", "Feedback", "Focus Groups", "Frequencies", "Funding", "Future", "General Population", "Health Services Accessibility", "Home", "Individual", "Institutional Review Boards", "Instruction", "Internet", "Language", "Manuals", "Market Research", "National Institute of Biomedical Imaging and Bioengineering", "Notification", "Observational Study", "Online Systems", "Participant", "Personal Health Records", "Play", "Privacy", "Public Health", "Reaction", "Readability", "Reporting", "Secure", "Specific qualifier value", "Surveys", "Symptoms", "System", "Technology", "Test Result", "Testing", "Time", "Vaccination", "authority", "base", "diaries", "digital", "digital health", "handheld mobile device", "home test", "repository" ], "approved": true } }, { "type": "Grant", "id": "9090", "attributes": { "award_id": "75N93020C00032-0-9999-2", "title": "COVID-19: Clinical Research Products Development Center (CRPMC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-16", "end_date": "2021-06-15", "award_amount": 1196744, "principal_investigator": { "id": 24891, "first_name": "NEERAJA", "last_name": "PUTTA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1795, "ror": "", "name": "FISHER BIOSERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1795, "ror": "", "name": "FISHER BIOSERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "NIAID has a requirement for the management and operation of a Clinical Research Products Management Center (CRPMC) to support NIAID-sponsored clinical research trials both domestically and internationally. This contract will provide pharmaceutical services and study product management by providing a cGMP-compliant facility, receipt, storage, labeling, packaging, repackaging, shipping, acquiring, and disposition of study products. This contract will provide cognitive pharmaceutical services including evaluating draft protocols; reviewing site pharmacy monitoring reports and maintaining a site audit pharmacy report database; providing study product storage and stability information, guidance in research pharmacy practice and study product management activities to clinical site pharmacists; and conducting Current Good Manufacturing Practice (cGMP) audits of manufacturing facilities. This project will support study product management and distribution of the study products for COVID-19 clinical trial A5401 (ACTIV-2 Outpatient Monoclonal Antibodies And Other Therapies).", "keywords": [ "AIDS clinical trial group", "COVID-19", "Clinical Research", "Clinical Trials", "Cognitive", "Contracts", "Databases", "International", "Label", "Monitor", "Monoclonal Antibodies", "National Institute of Allergy and Infectious Disease", "Outpatients", "Pharmaceutical Services", "Pharmacists", "Pharmacy facility", "Protocols documentation", "Reporting", "Research", "Shipping", "Site", "clinical research site", "manufacturing facility", "operation", "product development" ], "approved": true } }, { "type": "Grant", "id": "9091", "attributes": { "award_id": "75N93020C00032-P00003-9999-2", "title": "COVID-19: Clinical Research Products Management Center (CRPMC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-16", "end_date": "2021-06-15", "award_amount": 2273031, "principal_investigator": { "id": 24892, "first_name": "CARINA", "last_name": "REMGSAMAI-NHE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1795, "ror": "", "name": "FISHER BIOSERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1795, "ror": "", "name": "FISHER BIOSERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "NIAID has a requirement for the management and operation of a Clinical Research Products Management Center (CRPMC) to support NIAID-sponsored clinical research trials both domestically and internationally. This contract will provide pharmaceutical services and study product management by providing a cGMP-compliant facility, receipt, storage, labeling, packaging, repackaging, shipping, acquiring, and disposition of study products. This contract will provide cognitive pharmaceutical services including evaluating draft protocols; reviewing site pharmacy monitoring reports and maintaining a site audit pharmacy report database; providing study product storage and stability information, guidance in research pharmacy practice and study product management activities to clinical site pharmacists; and conducting Current Good Manufacturing Practice (cGMP) audits of manufacturing facilities. This project will support study product management and distribution of the study products for COVID-19 clinical trial A5401 (ACTIV-2 Outpatient Monoclonal Antibodies And Other Therapies).", "keywords": [ "AIDS clinical trial group", "COVID-19", "Clinical Research", "Clinical Trials", "Cognitive", "Contracts", "Databases", "International", "Label", "Monitor", "Monoclonal Antibodies", "National Institute of Allergy and Infectious Disease", "Outpatients", "Pharmaceutical Services", "Pharmacists", "Pharmacy facility", "Protocols documentation", "Reporting", "Research", "Shipping", "Site", "clinical research site", "manufacturing facility", "operation" ], "approved": true } }, { "type": "Grant", "id": "9093", "attributes": { "award_id": "75N95020C00010-P00005-9999-3", "title": "MODIFICATION TO DEOBLIGATE FUNDS.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-08", "end_date": "2021-02-28", "award_amount": 188591, "principal_investigator": { "id": 24128, "first_name": "SUHAS", "last_name": "SHARMA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The NCATS National COVID Cohort Collaborative (N3C) Data Enclave, a centralized and secure data platform featuring powerful analytics capabilities for online discovery, visualization and collaboration for researchers studying COVID-19. The data are robust in scale and scope and are transformed into a harmonized data set to help scientists study COVID 19, including potential risk factors, protective factors and long-term health consequences. The N3C Data Enclave is anticipated to be one of the largest collections of data on COVID-19 patients in the United States. Data analysis within the enclave is supported by both R and Python, the most widely used open-source platforms for statistical analysis and data science. Researchers requesting access to, or working within, the enclave are encouraged to assemble collaborative teams with diverse expertise in such areas as clinical research, statistical analysis and informatics to make the best use of the N3C Data Enclave. A core tenet of the enclave is that it is both accessible and secure, allowing researchers to pursue research in a safe environment conducive to collaborative discovery while also allowing for the deployment of a wide variety of open source tools and components.", "keywords": [ "Area", "COVID-19", "COVID-19 patient", "Clinical Research", "Collaborations", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Environment", "Funding", "Health", "Informatics", "Pythons", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Statistical Data Interpretation", "United States", "Visualization", "cohort", "coronavirus disease", "data enclave", "data harmonization", "open source", "open source tool", "protective factors" ], "approved": true } }, { "type": "Grant", "id": "9094", "attributes": { "award_id": "75N95020C00010-0-9999-1", "title": "NCATS RESEARCH SERVICES SECTION SUPPORT 2.0 (RSSS-2.0) POP 6/8/20 - 12/31/20.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-08", "end_date": "2020-12-31", "award_amount": 686597, "principal_investigator": { "id": 24128, "first_name": "SUHAS", "last_name": "SHARMA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The NCATS National COVID Cohort Collaborative (N3C) Data Enclave, a centralized and secure data platform featuring powerful analytics capabilities for online discovery, visualization and collaboration for researchers studying COVID-19. The data are robust in scale and scope and are transformed into a harmonized data set to help scientists study COVID 19, including potential risk factors, protective factors and long-term health consequences. The N3C Data Enclave is anticipated to be one of the largest collections of data on COVID-19 patients in the United States. Data analysis within the enclave is supported by both R and Python, the most widely used open-source platforms for statistical analysis and data science. Researchers requesting access to, or working within, the enclave are encouraged to assemble collaborative teams with diverse expertise in such areas as clinical research, statistical analysis and informatics to make the best use of the N3C Data Enclave. A core tenet of the enclave is that it is both accessible and secure, allowing researchers to pursue research in a safe environment conducive to collaborative discovery while also allowing for the deployment of a wide variety of open source tools and components.", "keywords": [ "Area", "COVID-19", "Clinical Research", "Collaborations", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Environment", "Health", "Informatics", "Patients", "Pythons", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Services", "Statistical Data Interpretation", "United States", "Visualization", "cohort", "coronavirus disease", "data enclave", "data harmonization", "open source", "protective factors", "tool" ], "approved": true } }, { "type": "Grant", "id": "9096", "attributes": { "award_id": "272201700011C-P00011-9999-2", "title": "SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-05", "end_date": "2021-05-31", "award_amount": 1500152, "principal_investigator": { "id": 24896, "first_name": "LAURIE", "last_name": "SOWER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1796, "ror": "", "name": "CHRYSALIS BIOTHERAPEUTICS, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1796, "ror": "", "name": "CHRYSALIS BIOTHERAPEUTICS, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Chrysalis proposes to repurpose their regenerative drug, TP508, to treat COVID-19, due to its ability to reduce effects of acute lung injury, prevent normal tissue damage and reduce inflammation. TP508 has an existing efficacy profile in tissue regeneration clinical trials, an extensive safety profile (600 human subjects with no adverse effects), and is GMP manufactured with sufficient inventory to enter COVID-19 clinical trials. The drug addresses underlying causes of ARDS, including loss of endothelial function.", "keywords": [ "2019-nCoV", "Acute Lung Injury", "Address", "Adult Respiratory Distress Syndrome", "Adverse effects", "Biological Assay", "COVID-19", "Clinical", "Clinical Trials", "Documentation", "Dose", "Endothelium", "Equipment and supply inventories", "Human", "Infection", "Inflammation", "Normal tissue morphology", "Patients", "Pharmaceutical Preparations", "Phase I Clinical Trials", "Phase II Clinical Trials", "SARS coronavirus", "Safety", "Schedule", "Work", "human subject", "preclinical study", "prevent", "regenerative", "tissue regeneration" ], "approved": true } }, { "type": "Grant", "id": "9115", "attributes": { "award_id": "75N92020C00010-P00001-9999-1", "title": "RADX TECH - TALIS BIOMEDICAL HIGHLY SCALABLE SARS-COV-2 RNA DETECTION IN MINUTES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 9750000, "principal_investigator": { "id": 24901, "first_name": "JENNIFER", "last_name": "BALDWIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "With over $100M investment by the top biotech Venture Capital funds, NIH, CARB-X, and DARPA, Talis has developed ultrafast, sensitive, scalable technology uniquely suitable for COVID-19 testing. The Talis technology performs rapid (as fast as 6 minutes) purification of SARS-CoV-2 RNA from large volumes of human specimens including swabs and saliva and detects SARS-CoV-2 RNA in under 5 minutes for high positives and under 10 minutes near the limit of detection (~10 copies/reaction). Talis will deploy this technology in a high-throughput format for laboratories (Talis HT) and at the point-of-care (POC) for minimally trained users (Talis One). With RADx support, Talis will scale this technology in three stages: (1) In June, to accelerate throughput of the currently installed diagnostic equipment, Talis will deliver reagent kits for rapid SARS-CoV-2 detection in 96-well format. (2) In July, to further increase testing throughput, Talis will launch automation solutions for common diagnostic laboratory platforms, making kits for 4 million tests available. (3) In September, Talis will launch its rapid COVID-19 Talis One POC test on a multiplexed cartridge, expandable to include influenza. Operated by a compact Talis One instrument, this cartridge enables fully automated, sensitive SARS-CoV-2 RNA detection in under 20 minutes. Talis HT and Talis One will be adaptable to mobile testing for rapid response contact tracing, worker screening, and outbreak response. Talis is requesting RADx support to scale up and accelerate manufacturing of tests and will commit significant funds for cost-sharing.", "keywords": [ "2019-nCoV", "Automation", "Biotechnology", "COVID-19", "COVID-19 detection", "COVID-19 testing", "Capital Financing", "Contact Tracing", "Cost Sharing", "Detection", "Diagnostic", "Diagnostic Equipment", "Disease Outbreaks", "Funding", "Human", "Influenza", "Investments", "Laboratories", "RADx", "RADx Tech", "RNA", "Reaction", "Reagent", "Saliva", "Specimen", "Swab", "Technology", "Testing", "Training", "United States National Institutes of Health", "detection limit", "instrument", "point of care", "point of care testing", "rapid testing", "response", "scale up", "screening" ], "approved": true } }, { "type": "Grant", "id": "9117", "attributes": { "award_id": "75N92020C00014-P00003-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244: EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 294500, "principal_investigator": { "id": 24903, "first_name": "INGO", "last_name": "CHAKRAVARTY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "To address the need for pandemic-scale deployment of the Accula SARS-CoV-2 Test, Mesa Biotech will scale-up manufacturing by rapid facility expansion to produce 60,000 tests per day. Current manufacturing output is approximately 2,000 tests/day. We propose a two phase manufacturing scale-up to increase output, over the four weeks following the availability of funds, to 6,000 tests/day through the addition of production lines and expansion of the existing facility that can be rapidly put in place. A second phase expansion of manufacturing capacity over the next four months will further increase capacity through addition of a new facility, additional dry room space and additional production lines to an output of up to 60,000 tests/day. Accula Dock instrument manufacturing capacity currently in place will support the production of 50 Dock instruments per day. Modest increases in Dock production at our current facility will increase this output to 200 Docks/day, producing additional 18,000 docks in the coming 4 months. Given that the Dock manufacturing process makes use of standard electronic device manufacturing methods, Dock manufacturing capacity may also be further augmented through the use of contract manufacturing. Therefore, the proposed effort focuses on test cassette production scale-up which requires specialized manufacturing processes best achieved by expansion of manufacturing capacity at Mesa Biotech.", "keywords": [ "Address", "Biotechnology", "COVID-19 test", "Contracts", "Docking", "Electronics", "Funding", "Methods", "Molecular", "Output", "Phase", "Production", "RADx", "Testing", "base", "cost", "instrument", "manufacturing process", "manufacturing scale-up", "pandemic disease", "programs", "scale up" ], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1424, "count": 14236 } } }